首页> 外文期刊>Journal of Endocrinological Investigation: Official Journal of the Italian Society of Endocrinology >A single-institution restrospective experience of brachytherapy in the treatment of pituitary tumors: transsphenoidal approach combined with (192)Ir-afterloading catheters.
【24h】

A single-institution restrospective experience of brachytherapy in the treatment of pituitary tumors: transsphenoidal approach combined with (192)Ir-afterloading catheters.

机译:近距离放射疗法在垂体瘤治疗中的单机构回顾性经验:经蝶窦入路结合(192)Ir后负荷导管。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND AND AIM: Radiotherapy may be used as an adjuvant treatment of pituitary adenomas. The aim of our study was to present our experience of multimodal treatment of pituitary adenomas, consisting in temporary implantation of (192)Ir-labeled wires following transphenoidal surgery. SUBJECTS AND METHODS: An observational investigation was performed on a series of 80 patients undergoing surgery (S) for pituitary adenomas between 1982 and 2000, some of whom received post-operative external beam radiotherapy (EBRT) (no.=19 between 1982 and 1990), brachytherapy (B) (no.=35, all after 1991), or both irradiation modalities (EBRT+B) (no.=14). The different treatments were compared in terms of hormonal normalization in the subgroup of patients with hypersecreting adenomas, tumor control, and side effects. RESULTS: Hormonal normalization was obtained in 84% of S+B patients and in 61% of S+EBRT patients. Tumor control was obtained in 74.3% of S+B patients and in 63.1% of S+EBRT patients. Anterior pituitary hormones deficits ranged from 8.6-34% in S+B patients and from 15.8-47.4% in S+EBRT patients, after a mean follow-up of 14 yr. The latter group also showed a higher rate of multiple deficits (42.1% vs 22.8%). Diabetes insipidus and other major complications were rare events in all groups. CONCLUSIONS: We presented one original experience regarding brachytherapy in the management of pituitary tumors, which turned out to be effective and safe. Additional prospective, and possibly randomized, studies should clarify whether in the era of 3-dimensional conformal radiotherapy and stereotactic radiotherapy this treatment modality may still have a role.
机译:背景与目的:放射治疗可用作垂体腺瘤的辅助治疗。本研究的目的是介绍我们对垂体腺瘤进行多式联运治疗的经验,包括在经蝶骨手术后临时植入(192)Ir标记的金属丝。研究对象和方法:对1982年至2000年间接受垂体腺瘤手术(S)的80例患者进行了观察性研究,其中一些患者接受了术后体外束放射疗法(EBRT)(1982年至1990年之间为19名) ),近距离放射治疗(B)(编号:35,全部于1991年以后)或两种照射方式(EBRT + B)(编号= 14)。比较了在高分泌腺瘤,肿瘤控制和副作用患者亚组中激素正常化方面不同的治疗方法。结果:84%的S + B患者和61%的S + EBRT患者获得了激素正常化。 74.3%的S + B患者和63.1%的S + EBRT患者获得了肿瘤控制。平均随访14年后,S + B患者的垂体前叶激素缺陷范围为8.6-34%,S + EBRT患者为15.8-47.4%。后一组还显示出更高的多重缺陷率(42.1%对22.8%)。在所有组中,尿崩症和其他主要并发症很少见。结论:我们提出了一种关于垂体瘤近距离放射治疗的原始经验,事实证明这种方法是有效和安全的。额外的前瞻性研究(可能是随机研究)应阐明在3D保形放射疗法和立体定向放射疗法时代,这种治疗方式是否仍可能起作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号